Literature DB >> 11240819

Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer.

R. Halperin1, E. Hadas, R. Langer, I. Bukovsky, D. Schneider.   

Abstract

Halperin R, Hadas E, Langer R, Bukovsky I, Schneider D. Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer. The aim of this study was to examine the hormonal milieu in peritoneal fluid in ovarian cancer and control patients, and to try to identify hormonal parameters specific for ovarian cancer. The study included 41 patients: 21 with ovarian cancer and 20 patients with benign disease, constituting a control group. The peritoneal fluid and serum samples from these patients were subjected to analysis of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone, testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS), and levels were compared between the two study groups. In addition, peritoneal fluid samples were subjected to cytologic examination and serum samples were assayed for CA 125. All the examined hormonal parameters in peritoneal fluid demonstrated a significant increase in ovarian cancer compared to control patients (P < 0.04). No significant difference in serum levels of the measured hormones was observed between the 2 groups. In order to further discriminate between patients with and without ovarian cancer, the sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of each parameter were calculated. Determination of LH in peritoneal fluid provided sensitivity, specificity and diagnostic accuracy of 100%. In conclusion, patients with ovarian cancer as compared to controls demonstrate significantly increased levels of gonadotropins and ovarian hormones in peritoneal fluid, thus supporting the theory of association between ovarian cancer and specific hormonal milieu. In addition, our results provide a novel hormonal marker for discrimination between patients with and without ovarian cancer.

Entities:  

Year:  1999        PMID: 11240819     DOI: 10.1046/j.1525-1438.1999.99075.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.

Authors:  Michelle K Y Siu; Hoi Yan Chan; Daniel S H Kong; Esther S Y Wong; Oscar G W Wong; Hextan Y S Ngan; Kar Fai Tam; Hongquan Zhang; Zhilun Li; Queeny K Y Chan; Sai Wah Tsao; Staffan Strömblad; Annie N Y Cheung
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-06       Impact factor: 11.205

Review 2.  Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer.

Authors:  John J Peluso
Journal:  Steroids       Date:  2011-03-01       Impact factor: 2.668

3.  FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor.

Authors:  Y Li; S Ganta; C Cheng; R Craig; R R Ganta; L C Freeman
Journal:  Mol Cell Endocrinol       Date:  2007-01-16       Impact factor: 4.102

4.  Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway.

Authors:  Xiao Yang; Jing Wang; Wen-Ping Li; Zhi-Jun Jin; Xiao-Jun Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.

Authors:  Alice W Lee; Jonathan P Tyrer; Jennifer A Doherty; Douglas A Stram; Jolanta Kupryjanczyk; Agnieszka Dansonka-Mieszkowska; Joanna Plisiecka-Halasa; Beata Spiewankiewicz; Emily J Myers; Georgia Chenevix-Trench; Peter A Fasching; Matthias W Beckmann; Arif B Ekici; Alexander Hein; Ignace Vergote; Els Van Nieuwenhuysen; Diether Lambrechts; Kristine G Wicklund; Ursula Eilber; Shan Wang-Gohrke; Jenny Chang-Claude; Anja Rudolph; Lara Sucheston-Campbell; Kunle Odunsi; Kirsten B Moysich; Yurii B Shvetsov; Pamela J Thompson; Marc T Goodman; Lynne R Wilkens; Thilo Dörk; Peter Hillemanns; Matthias Dürst; Ingo B Runnebaum; Natalia Bogdanova; Liisa M Pelttari; Heli Nevanlinna; Arto Leminen; Robert P Edwards; Joseph L Kelley; Philipp Harter; Ira Schwaab; Florian Heitz; Andreas du Bois; Sandra Orsulic; Jenny Lester; Christine Walsh; Beth Y Karlan; Estrid Hogdall; Susanne K Kjaer; Allan Jensen; Robert A Vierkant; Julie M Cunningham; Ellen L Goode; Brooke L Fridley; Melissa C Southey; Graham G Giles; Fiona Bruinsma; Xifeng Wu; Michelle A T Hildebrandt; Karen Lu; Dong Liang; Maria Bisogna; Douglas A Levine; Rachel Palmieri Weber; Joellen M Schildkraut; Edwin S Iversen; Andrew Berchuck; Kathryn L Terry; Daniel W Cramer; Shelley S Tworoger; Elizabeth M Poole; Sara H Olson; Irene Orlow; Elisa V Bandera; Line Bjorge; Ingvild L Tangen; Helga B Salvesen; Camilla Krakstad; Leon F A G Massuger; Lambertus A Kiemeney; Katja K H Aben; Anne M van Altena; Yukie Bean; Tanja Pejovic; Melissa Kellar; Nhu D Le; Linda S Cook; Linda E Kelemen; Angela Brooks-Wilson; Jan Lubinski; Jacek Gronwald; Cezary Cybulski; Anna Jakubowska; Nicolas Wentzensen; Louise A Brinton; Jolanta Lissowska; Hannah Yang; Lotte Nedergaard; Lene Lundvall; Claus Hogdall; Honglin Song; Ian G Campbell; Diana Eccles; Rosalind Glasspool; Nadeem Siddiqui; Karen Carty; James Paul; Iain A McNeish; Weiva Sieh; Valerie McGuire; Joseph H Rothstein; Alice S Whittemore; John R McLaughlin; Harvey A Risch; Catherine M Phelan; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Susan J Ramus; Aleksandra Gentry-Maharaj; Patricia Harrington; Malcolm C Pike; Francesmary Modugno; Mary Anne Rossing; Roberta B Ness; Paul D P Pharoah; Daniel O Stram; Anna H Wu; Celeste Leigh Pearce
Journal:  Gynecol Oncol       Date:  2014-12-17       Impact factor: 5.482

6.  Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice.

Authors:  Mary J Laws; Athilakshmi Kannan; Sandeep Pawar; Wanda M Haschek; Milan K Bagchi; Indrani C Bagchi
Journal:  PLoS Genet       Date:  2014-03-06       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.